Pharmaceutical - Pharmaceutical, Cardio-vascular

Filter

Popular Filters

1 to 25 of 435 results

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

10-07-2014

USA-based Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Japanese…

andexanet alfaCardio-vascularDaiichi SankyoedoxabanJapanLicensingPharmaceuticalPortola PharmaceuticalsResearchSavaysaUSA

Proveca reaches agreement with EMA over heart failure drug for children

Proveca reaches agreement with EMA over heart failure drug for children

10-07-2014

UK pharmaceutical company Proveca has reached its fourth key agreement with the European Medicines Agency…

CaptoprilCardio-vascularPharmaceuticalRegulationUK

AstraZeneca in research accord with Max Planck Institute

AstraZeneca in research accord with Max Planck Institute

08-07-2014

Anglo-Swedish pharma major AstraZeneca has entered an agreement with the Max Planck Institute of Molecular…

AstraZenecaCardio-vascularMetabolicsPharmaceuticalResearch

Pozen re-files for US approval of PA8140/PA32540

Pozen re-files for US approval of PA8140/PA32540

02-07-2014

US drug firm Pozen has resubmitted the New Drug Application for PA8140/PA32540 (aspirin and omeprazole)…

AspirinCardio-vascularOmeprazolePA8140/PA32540PharmaceuticalPozenRegulationUSA

Six new drugs recommended for approval by EMA’s CHMP

Six new drugs recommended for approval by EMA’s CHMP

27-06-2014

At its end-June meetings, the European Medicines Agency’s Committee for Medicinal Products for Human…

AbrasiaAnti-viralsBristol-Myers SquibbCardio-vascularDaklinzaDiabetesEli LillyEuropeFreseniusGE HealthcarePharmaceuticalRegulationTriumeqVelphoroVifor PharmaVizamyl

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

26-06-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation to idarucizumab, an…

Boehringer IngelheimCardio-vascularidarucizumabPharmaceuticalPradaxaRegulationResearchUSA

FDA review of CV risks for diabetics taking olmesartan not conclusive

FDA review of CV risks for diabetics taking olmesartan not conclusive

25-06-2014

The US Food and Drug Administration has completed its safety review and has found no clear evidence of…

BenicarCardio-vascularDaiichi SankyoDiabetesolmesartanPharmaceuticalRegulationUSA

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

23-06-2014

Japan’s largest drugmaker Takeda Pharmaceuticals has updated on the third-party surrounding the results…

BlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalResearchTakeda Pharmaceutical

Ivabradine and CV events in angina patients under review in Australia

Ivabradine and CV events in angina patients under review in Australia

23-06-2014

Australian pharma regulator the Therapeutic Goods Administration (TGA) is reviewing new information regarding…

AustraliaCardio-vascularCoralanivabradinePharmaceuticalRegulationServier

UK’s NICE draft guidance recommends Lilly’s Efient

UK’s NICE draft guidance recommends Lilly’s Efient

20-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has today published…

Cardio-vascularEfientEli LillyPharmaceuticalPricingRegulationUK

New NICE guidance on cardiovascular treatments

New NICE guidance on cardiovascular treatments

18-06-2014

Thousands of people with atrial fibrillation could be saved from strokes, disability or death because…

Cardio-vascularPharmaceuticalRegulationUKWarfarin Sodium

China cardiovascular drugs market set to grow to 45 billion renminbi by 2018

China cardiovascular drugs market set to grow to 45 billion renminbi by 2018

13-06-2014

A new report titled Research on China Cardiovascular Drugs Industry 2014-2018, says that, in the next…

Cardio-vascularChinaMarkets & MarketingPharmaceutical

Statin drugs may do more harm than good, article claims

13-06-2014

Statins, already the most prescribed drugs in history, are being recommended for more and more patients…

Cardio-vascularHealthcarePharmaceutical

Orexigen stock falls after FDA extends review of obesity drug

Orexigen stock falls after FDA extends review of obesity drug

11-06-2014

Obesity-focused US biopharmaceutical company Orexigen Therapeutics says that the US Food and Drug Administration…

AnorecticsBiopharmaceuticalCardio-vascularContraveHealth Medical PharmaNB32Orexigen TherapeuticsPharmaceuticalPharmacologyRegulationUSA

High price of novel antithrombotics a major deterrent to patient access in China

High price of novel antithrombotics a major deterrent to patient access in China

10-06-2014

The high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs)…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularChinaEliquisMarkets & MarketingPharmaceuticalPradaxaPricingWarfarin SodiumXarelto

Boehringer’s Pradaxa gains added indication in Europe

Boehringer’s Pradaxa gains added indication in Europe

06-06-2014

German family-owned pharma major Boehringer Ingelheim said today that its blood thinner Pradaxa (dabigatran…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaRegulation

GSK launches Phase III trial with losmapimod in acute coronary syndrome

GSK launches Phase III trial with losmapimod in acute coronary syndrome

06-06-2014

UK pharma major GlaxoSmithKline has announced the start of a pivotal Phase III study, LATITUDE-TIMI 60,…

Cardio-vascularCardiologyGlaxoSmithKlinelosmapimodPharmaceuticalResearchUK

Global anti-hypertensives market will see decline as key patents expire

Global anti-hypertensives market will see decline as key patents expire

04-06-2014

Multiple major drug patent expiries will cause the global anti-hypertensive drug market value to decline…

Cardio-vascularMarkets & MarketingPharmaceuticalResearch

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

02-06-2014

After facing more than 2,000 law suits in the USA, claiming Pradaxa (dabigatran) caused severe or fatal…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceutical

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

28-05-2014

German family-owned pharma major Boehringer Ingelheim says it has reached a comprehensive settlement…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceuticalPradaxaUSA

Daiichi Sankyo launches blood thinner Efient in Japan

27-05-2014

Daiichi Sankyo said this morning that it has launched its anti-blood clotting drug Efient (prasugrel…

Cardio-vascularDaiichi SankyoEfientJapanMarkets & MarketingPharmaceuticalRegulation

EMA/CHMP again rejects Novartis’ serelaxin for AHF

26-05-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has for a second…

Cardio-vascularEuropeNovartisPharmaceuticalReasanzRegulationserelaxin

1 to 25 of 435 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top